Recent in vitro experiments showed that blocking GM-CSF and gemcitabine combined with chemotherapy inhibited the differentiation of MDSCs in pancreatic cancer, thereby improving the function of killer T lymphocytes in pancreatic cancer (96). Here, CSF2 is linked to pancreatic neoplasm.